Who are Levothyroxine Tablet's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Levoxyl, L-thyroxine (L-T4), Thyroid hormone, Tirosint®-SOL, Levothyroxine-Na + iodide, Liothyronine and Levothyroxine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/levothyroxine-tablet.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Levothyroxine Tablet — Competitive Intelligence Brief

Levothyroxine Tablet (Levothyroxine Tablet) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Thyroid hormone replacement. Area: Endocrinology.

marketed Thyroid hormone replacement Thyroid hormone receptor (TR-alpha and TR-beta) Endocrinology Small molecule Live · refreshed every 30 min

Target snapshot

Levothyroxine Tablet (Levothyroxine Tablet) — University of California, Los Angeles. Levothyroxine is a synthetic thyroid hormone that replaces or supplements endogenous thyroid hormone to restore normal metabolic function.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Levothyroxine Tablet TARGET	Levothyroxine Tablet	University of California, Los Angeles	marketed	Thyroid hormone replacement	Thyroid hormone receptor (TR-alpha and TR-beta)
Levoxyl	Levothyroxine Sodium	Pfizer Inc.	marketed	Thyroid hormone replacement	Thyroid receptor proteins attached to DNA
L-thyroxine (L-T4)	L-thyroxine (L-T4)	Oregon Health and Science University	marketed	Thyroid hormone replacement	Thyroid hormone receptor (TR-alpha, TR-beta)
Thyroid hormone	Thyroid hormone	Merck Sharp & Dohme LLC	marketed	Thyroid hormone replacement	Thyroid hormone receptors (TR-alpha, TR-beta)
Tirosint®-SOL	Tirosint®-SOL	IBSA Institut Biochimique SA	marketed	Thyroid hormone replacement	Thyroid hormone receptors (TR-alpha and TR-beta)
Levothyroxine-Na + iodide	Levothyroxine-Na + iodide	Sanofi	marketed	Thyroid hormone replacement therapy	Thyroid hormone receptors (TR-alpha and TR-beta)
Liothyronine and Levothyroxine	Liothyronine and Levothyroxine	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	marketed	Thyroid hormone replacement	Thyroid hormone receptor alpha and beta (TRα, TRβ)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Thyroid hormone replacement class)

Pfizer Inc. · 2 drugs in this class
Daewon Pharmaceutical Co., Ltd. · 1 drug in this class
IBSA Institut Biochimique SA · 1 drug in this class
M. Medici · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class
Meyer Children's Hospital IRCCS · 1 drug in this class
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · 1 drug in this class
Oregon Health and Science University · 1 drug in this class
Sanofi · 1 drug in this class
Takeda · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Levothyroxine Tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/levothyroxine-tablet. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab